Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Cancer Management and Research ◽

10.2147/cmar.s284556 ◽

2020 ◽

Vol Volume 12 ◽

pp. 12905-12913

Author(s):

Jiangping Yang ◽

Jiaqi Han ◽

Maolang Tian ◽

Kun Tian ◽

Wenjun Liao ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as frist-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): A UK perspective

European Journal of Cancer ◽

10.1016/s0959-8049(02)80202-7 ◽

2002 ◽

Vol 38 (11) ◽

pp. S68

Author(s):

R Simons

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Advanced Breast ◽

Effectiveness Analysis ◽

Line Therapy

Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women with Hormone Receptor-Positive Advanced Breast Cancer in The UK

Value in Health ◽

10.1016/j.jval.2017.08.214 ◽

2017 ◽

Vol 20 (9) ◽

pp. A435

Author(s):

C Livings ◽

N Jones ◽

E Bertranou ◽

S Large ◽

H Phelps ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

The Uk

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Contemporary Clinical Trials Communications ◽

10.1016/j.conctc.2018.05.012 ◽

2018 ◽

Vol 10 ◽

pp. 190-192

Author(s):

Filipa Lynce ◽

Mervat Saleh ◽

Ayesha Shajahan-Haq ◽

Christopher Gallagher ◽

Asma Dilawari ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

Advanced Breast Cancer ◽

African American Women ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Safety Study ◽

American Women ◽

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Cited By ~ 87

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists

Clinical Breast Cancer ◽

10.1016/j.clbc.2014.03.002 ◽

2014 ◽

Vol 14 (5) ◽

pp. 297-308 ◽

Cited By ~ 20

Author(s):

Denise A. Yardley

Keyword(s):

Breast Cancer ◽

Adverse Event ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Mtor Inhibitors ◽

Advanced Breast ◽

Event Management ◽

Adverse Event Management

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer

The Breast ◽

10.1016/j.breast.2014.09.006 ◽

2014 ◽

Vol 23 (6) ◽

pp. 710-720 ◽

Cited By ~ 24

Author(s):

Elsa Dalmau ◽

Alejandra Armengol-Alonso ◽

Montserrat Muñoz ◽

Miguel Ángel Seguí-Palmer

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Current Status ◽

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal of Bone Oncology ◽

10.1016/j.jbo.2018.09.010 ◽

2019 ◽

Vol 14 ◽

pp. 100199 ◽

Cited By ~ 1

Author(s):

Peyman Hadji ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Mammalian Target Of Rapamycin ◽

Advanced Breast ◽

Phase Iiib ◽

The Impact

Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdy424.011 ◽

2018 ◽

Vol 29 ◽

pp. viii709 ◽

Cited By ~ 1

Author(s):

Z. Jiang ◽

W. Li ◽

X. Hu ◽

Q. Zhang ◽

T. Sun ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Histone Deacetylase ◽

Hdac Inhibitor ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Subtype Selective